Stock Expert AI

Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.

Abbott Laboratories
ABT - NYSE - $103.70 (as of ) ▲ +1.16%
-
Earnings Thu 28 Jan

Abbott opens the
books on Thursday evening.

The median of 10 price targets is $1201, stock is $104, +15.7% vs the analyst consensus median. Stock move on the next trading day: +2.0%.

↓ summary below
Quick Take - in 40 seconds ·
C-
Council 1/6 - Historical V1 score 55

C- — FMP rating1. Form 4: 6 transactions1.

Quick Answer

Abbott Laboratories (ABT) Q4 consensus: revenue $13.2B1, EPS $1.641. 0 consecutive quarters of beat1.

$1.64 EPS Estimate Last year $1.50 - +9% YoY
0 Beat Streak Expectations beaten consecutively for the last 0 quarters

Q3 FY26 EPS $1.42 vs $1.42 estimate: in line1. Stock move on D+1: +2.0%1.

Next report

What to watch in Q4 FY26 (Jan 28, 2027)

  • EPS: consensus $1.64, against $1.50 in the same quarter a year ago (+9%).
  • Revenue: consensus $13.2B.

Watchlist

6 metrics stand out this quarter.

7% Investor Focus

Q3 Growth Acceleration

Abbott's Q3 sales grew 7% and EPS grew 9%, an acceleration versus the first half of the year.

Robert Ford, CEO - Q3 FY26 Earnings Call - October 21, 2026
57.2% Risk Indicator

Gross Margin Expansion

Adjusted gross margin reached 57.2% of sales, up 140 basis points from the prior year.

Philip Boudreau, CFO - Q3 FY26 Earnings Call - October 21, 2026
$1.62 Expectation / Guide

Q4 Eps Guidance

Abbott guides Q4 adjusted EPS to a range of $1.62 to $1.67.

Philip Boudreau, CFO - Q3 FY26 Earnings Call - October 21, 2026
50 to 100 basis points Investor Focus

Post Separation Profile

Excluding nutrition, Abbott expects sales growth to accelerate by 50 to 100 basis points and operating margin to rise by approximately 100 basis points.

"we would expect sales growth to accelerate by 50 to 100 basis points, gross margin as a percent of sales to increase by more than 200 basis points, and an operating margin as a percent of sales to increase by approximately 100 basis points."

- Philip Boudreau, CFO - Q3 FY26 Earnings Call - October 21, 2026
$8.5 billion Investor Focus

Nutrition Separation

Abbott plans to separate its nutrition business, with about $8.5 billion in annual sales, into an independent publicly traded company.

"With approximately $8.5 billion in annual sales, 16,000 employees, and 14 manufacturing sites, this will be the largest globally scaled pure-play company in the healthy nutrition market."

- Robert Ford, CEO - Q3 FY26 Earnings Call - October 21, 2026
high teens Investor Focus

Electrophysiology Acceleration

Electrophysiology growth is accelerating, with U.S. growth in the high teens and above 20% excluding LAA, driven by adoption of the Volt PFA catheter.

Robert Ford, CEO - Q3 FY26 Earnings Call - October 21, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 6 perspectives, and Munger lens point in the same direction?

Council Score 1 / 6 Bullish

6 investor frameworks. 1 bullish (Ray Dalio), 1 bearish (Ken Griffin), 4 neutral (Jim Simons, Klarman, Buffett, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +15.7%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 54
Klarman value - target upside +15.7%
Buffett quality - ROE score 1/5
Munger valuation - target upside +15.7%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthWeak
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCTight
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
54.0 RSI 54.0 balanced, 50d below
MACD
-1.40 price below 50d - resistance dominant
50d MA
$105 stock 1.4% below - short-term resistance
200d MA
$102 stock 1.5% above - long-term support
Volume (10d)
-7% decrease - low participation
Resistance
$120
Analyst median target - upgrade trigger if broken
Current
$104
Pre-earnings position
Support
$87
Invalidation - close below this is a technical breakdown
Pattern
Range
$87-$120 band - earnings breakout/breakdown trigger

Past Performance

4 quarters shown.

IN LINE
Q4 FY25
$1.50 vs $1.50 est · Next-day price move: -1.1%
BEAT
Q1 FY26
$1.15 vs $1.14 est · Next-day price move: +1.4%
BEAT
Q2 FY26
$1.31 vs $1.28 est · Next-day price move: +1.9%
IN LINE
Q3 FY26
$1.42 vs $1.42 est · Next-day price move: +2.0%

Three scenarios: what could happen?

Backlog concentration

No RPO/backlog concentration disclosed in Q3 earnings call.

Insider trading signal

Form 4 Q3 FY26: 6 transactions, net -$45.75M1.

Executive Action Amount Date
MCCOY JOHN A. JR. VICE PRESIDENT AND CONTROLLER Sale -$3.0K 2026-09-03
Ford Robert B director, CHAIRMAN AND CEO Sale -$25.26M 2026-08-27
Ford Robert B director, CHAIRMAN AND CEO Sale -$20.95M 2026-08-27
Morrone Louis H. EXECUTIVE VICE PRESIDENT Sale -$642.5K 2026-08-13
Stratton John G director Purchase +$173.6K 2026-06-18
STARKS DANIEL J director Purchase +$926.5K 2026-04-28

6 transactions · 4 sales / 2 purchases = net negative flow. Not large in absolute terms against a $179.4B market cap.

CapEx shock

Q3 CapEx $399.0M1. Q3 op margin 11.3%1 - this level in Q4 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q4 EPS > $1.64 + CapEx discipline
Threshold: EPS > $1.641.
Target: Break above median target $1201; high target $1301 upper bound.
Scenario B - In-Line
EPS approx $1.64 + CapEx < $399.0M
Threshold: EPS approx $1.641, Q4 CapEx < $399.0M1.
Target: Consolidation in the band between current $1041 and median $1201.
Scenario C - Miss
EPS < $1.59 or CapEx >= $399.0M
Threshold: EPS < $1.591.
Current price $104 — above SMA200 $1021.

Market Outlook

What do analysts say? 10 price targets · 29 ratings

Wall Street Consensus
$120
12-month median target price (+15.7% gap to the analyst consensus median)
24
BUY
5
HOLD
0
SELL
Risk Management
$87
Invalidation level - critical support threshold
$105 - 50-day MA (below, -1.4%)
$102 - 200-day MA (above, +1.5%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - ABT Q4 FY26
C-

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q4 EPS threshold $1.641, CapEx threshold "below $399.0M". Two anchors, three scenarios.

Comparison Stock Expert AI is free today — no credit card.

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Jan 28, 2027EARNINGSQ4 FY26 results (after market close) + earnings call
Jan 29, 2027PRICEFirst trading day after earnings - 200dMA test + IV crush
Mar 1, 2027 – Mar 31, 2027FILING10-K due within 60–90 days of fiscal year end (by Mar 1, 2027 – Mar 31, 2027); the exact deadline depends on filer status
~Apr 30, 2027EARNINGSQ1 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the ABT Q4 FY26 earnings preview cover?

This Abbott Laboratories (ABT) Q4 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in ABT Q4 FY26 earnings?

Abbott Laboratories (ABT): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

Abbott Laboratories (ABT): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

Abbott Laboratories (ABT): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded